Literature DB >> 7417953

Curative potential of combined modality therapy for advanced Hodgkin's disease.

L R Farber, L R Prosnitz, E C Cadman, R Lutes, J R Bertino, D B Fischer.   

Abstract

During the period from 1969 through 1977, 124 patients with advanced Hodgkin's disease underwent treatment with combination chemotherapy and radiotherapy. Sixty-three cases were previously untreated, and 61 were relapses following radical radiotherapy for localized Hodgkin's disease. No patient in this series had received prior chemotherapy. Of 102 patients (84%) who have entered complete remission, 92 remain in complete remission with a median follow up time of five years, 10 patients having relapsed, and acute leukemia having developed in 2. The cumulative survival rate for all 124 patients is 80% at five years; the relapse-free survival rate is 74%. In many, if not most cases, the Hodgkin's disease appears to be cured. We have also identified two subgroups of patients for whom the prognosis is worse than for patients with advanced-stage disease as a whole. Patients over the age of 40 years have a five-year survival rate of only 45%, compared with 89% for all other patients. Those Stage IV patients with multiple extranodal sites of involvement have a five-year survival rate of 48%, compared with 81% for other Stage IV patients with only a single extranodal site involved.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7417953     DOI: 10.1002/1097-0142(19801001)46:7<1509::aid-cncr2820460702>3.0.co;2-t

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

Review 1.  Current approaches to the treatment of advanced-stage Hodgkin's disease.

Authors:  J J Rusthoven
Journal:  CMAJ       Date:  1986-09-01       Impact factor: 8.262

Review 2.  Current management of Hodgkin's disease.

Authors:  B C Behrens; R C Young; V T DeVita
Journal:  Drugs       Date:  1985-10       Impact factor: 9.546

Review 3.  The role of autografting in lymphoma.

Authors:  D W Milligan; S G Long
Journal:  Postgrad Med J       Date:  1994-07       Impact factor: 2.401

Review 4.  Primary multifocal osseous Hodgkin disease: a case report and review of the literature.

Authors:  C Gebert; J Hardes; H Ahrens; H Buerger; W Winkelmann; G Gosheger
Journal:  J Cancer Res Clin Oncol       Date:  2004-12-15       Impact factor: 4.553

5.  Prognostic factors in COPP-treated patients with Hodgkin's disease.

Authors:  W Gassmann; L Perenyi; N Schmitz; W Kayser; H Pralle; H Löffler
Journal:  Blut       Date:  1982-06

6.  Combination chemotherapy for the treatment of Hodgkin's disease in relapse. Results with lomustine (CCNU), melphalan (Alkeran), and vindesine (DVA) alone (CAD) and in alternation with MOPP and doxorubicin (Adriamycin), bleomycin, and vinblastine (ABV).

Authors:  D J Straus; J Myers; B Koziner; B J Lee; B D Clarkson
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.